Exchange: NASDAQ·Updated 07:54 PM EDT
News
all
press releases
The Nasdaq Stories Traders Can't Ignore
Here are today’s catalysts that are changing the narrative. $NTHI, $IPST, $OABI, $LLY, $HIVE, and $IVF
24-7 Market News
More News
Why Is Omniab Stock Rallying After Eli Lilly Deal?
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarketread more...
Benzinga
OmniAb Lands Lilly and Raises Guidance: $370M Deal Puts OABI’s Discovery Platform in the Spotlight
OmniAb (NASDAQ:OABI) may be one of the more interesting picks-and-shovels stories emerging in biotech, and its latest deal with Eli Lilly & Company (NYSE:LLY) could be another indication that the pharmaceutical industry sees value in the company’s technology rather than simply another early-stage drug program.
24-7 Market News
OmniAb Raises 2026 Financial Guidance
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. Recent business development and licensing...
Business Wire
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages...
Business Wire
OmniAb (OABI) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of +54.55% and +149.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and six months ended June 30, 2026, provided operating and partner program progress, and updated 2026...
Business Wire
OmniAb to Report Second Quarter 2026 Financial Results on August 6
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced the Company will report financial results for the three and six months ended June 30, 2026, after the close of the U.S. financial markets on...
Business Wire
OmniAb Names Amechi Nwachuku Chief Operating Officer
OmniAb, Inc. (NASDAQ:OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, announces that it has appointed Amechi Nwachuku to the newly-created position of Executive Vice President and Chief Operating Officer, effective today. Mr...
Business Wire

Advertisement|Remove ads.